Which Is a Better Investment, ADMA Biologics Inc or Axsome Therapeutics Inc Stock?

view original post

Featured Tickers:

Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Axsome Therapeutics Inc or ADMA Biologics Inc because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Axsome Therapeutics Inc and ADMA Biologics Inc compare based on key financial metrics to determine which better meets your investment needs.

About Axsome Therapeutics Inc and ADMA Biologics Inc

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company’s two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer’s disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

Latest Pharmaceuticals and Axsome Therapeutics Inc, ADMA Biologics Inc Stock News

As of May 13, 2024, Axsome Therapeutics Inc had a $3.4 billion market capitalization, compared to the Pharmaceuticals median of $121.7 million. Axsome Therapeutics Inc’s stock is NA in 2024, NA in the previous five trading days and down 2.99% in the past year.

Currently, Axsome Therapeutics Inc does not have a price-earnings ratio. Axsome Therapeutics Inc’s trailing 12-month revenue is $251.0 million with a -118.1% net profit margin. Year-over-year quarterly sales growth most recently was -20.7%. Analysts expect adjusted earnings to reach $-4.830 per share for the current fiscal year. Axsome Therapeutics Inc does not currently pay a dividend.

Currently, ADMA Biologics Inc does not have a price-earnings ratio. ADMA Biologics Inc’s trailing 12-month revenue is $258.2 million with a -1.4% net profit margin. Year-over-year quarterly sales growth most recently was 43.9%. Analysts expect adjusted earnings to reach $0.352 per share for the current fiscal year. ADMA Biologics Inc does not currently pay a dividend.

How We Compare Axsome Therapeutics Inc and ADMA Biologics Inc Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Axsome Therapeutics Inc and ADMA Biologics Inc’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions